Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.

doi:10.1093/neuonc/nox216

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.

Neuro-oncology - 18 May 2018

Pfaff Elke, Kessler Tobias, Balasubramanian Gnana Prakash, Berberich Anne, Schrimpf Daniel, Wick Antje, Debus Jürgen, Unterberg Andreas, Bendszus Martin, Herold-Mende Christel, Capper David, Schenkel Irini, Eisenmenger Andreas, Dettmer Susan, Brors Benedikt, Platten Michael, Pfister Stefan M, von Deimling Andreas, Jones David T W, Wick Wolfgang, Sahm Felix

Abstract excerpt

Background: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma without hypermethylated MGMT promoter is largely resistant to treatment with temozolomide. These patients are in particular need of new treatment approaches, which are offered by biomarker-driven clinical trials with targeted drugs based on molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Exome Sequencing

Share to Feasibility Studies

Share to Glioblastoma

Share to Pilot Projects

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 29165638
DOI: 10.1093/neuonc/nox216
PMCID: PMC5961072

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.PMID 29165638Read ↗

Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.Semantic proximity Read ↗

Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study.Semantic proximity Read ↗

Molecular neuro-oncology in clinical practice: a new horizon.Semantic proximity Read ↗

Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas.Semantic proximity Read ↗

Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for brain tumorsSemantic proximity Read ↗

Predictive and Prognostic Significance of Molecular Biomarkers in GlioblastomaSemantic proximity Read ↗

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.Semantic proximity Read ↗

Current status of DNA methylation profiling in neuro-oncology as a diagnostic support tool: A reviewSemantic proximity Read ↗

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.Semantic proximity Read ↗

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.Semantic proximity Read ↗

Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of GlioblastomaSemantic proximity Read ↗

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.